Search Results for “FDA” – Page 179 – media

Breakthrough status for Roche’s autism drug

Roche’s balovaptan has picked up a Breakthrough Therapy Designation in the US for its potential as a treatment for people with autism spectrum disorder (ASD), potentially placing the drug on a faster path to market.
- Source: pharmatimes
- 621
- February 5, 2018
ASD balovaptan New Approvals Roche
NHS launches online care plan to empower end of life patients

The NHS has launched a service that allows patients to share their urgent and end of life care wishes.
- Source: Digital Health Age
- 603
- January 31, 2018
digital health end of life healthcare NHS Policy
AstraZeneca’s Three-in-One COPD Inhaler Succeeds in Phase III Trial

AstraZeneca has GlaxoSmithKline and its chronic obstructive pulmonary disease (COPD) treatment Trelegy Ellipta squarely in its sights. This morning, AstraZeneca revealed Phase III data that shows its experimental three-in-one inhaler PT010 improved lung function in patients.
- Source: Biospace
- 586
- January 29, 2018
Clinical Trials COPD inhaler
Cybersecurity for Medical Device Endpoints

With the recent, highly publicized incidents of identity theft, ransomware and malware attacks directed at healthcare facilities, the medical device community is on high-security alert.
- Source: WIBU Systems
- 793
- January 29, 2018
cybersecurity FDA Market Views medical device
Remote patient monitoring startup LindaCare lands $8.6M from Phillips

Remote patient monitoring company LindaCare announced on Friday that they landed $8.6 million (€7 million) in Series B funding with participation by Philips, PMV, Capricorn ICT Arkiv, and Connecticut Innovations.
- Source: MobiHealthNews
- 613
- January 26, 2018
Company Insight digital health financing remote patient monitoring
Novartis, feeling the heat from head-to-head rivals, pulls Arzerra outside the U.S.

The commercial life for Novartis’ Arzerra outside the U.S. is coming to an end.
- Source: Fiercepharma
- 543
- January 25, 2018
Arzerra CLL Company Insight
Amgen Jumps as Migraine Drug Wows in Late-Stage Study

Amgen’s migraine drug Aimovig continues to impress with its efficacy in late-stage studies. On Monday, the company revealed Phase IIIb data that demonstrated the drug is also effective in reducing the number of episodic headaches in patients who have not responded to previous treatments.
- Source: biospace
- 616
- January 25, 2018
Aimovig Amgen Clinical Trials episodic headaches migraine
Merck KGaA taps UK cancer research organizations to feed pipeline

After an R&D drought that lasted more than a decade, Merck KGaA may be coming out of the desert. Following two recent drug approvals, including the landmark FDA OK for checkpoint inhibitor Bavencio, the German Merck is now entering an R&D collaboration that might help fill its pipeline with new cancer drug contenders.
- Source: Endpts
- 562
- January 23, 2018
Bavencio cancer inhibitor Market Views
Aspyrian Therapeutics Inc. announces successful advances in RM-1929 clinical development

Aspyrian Therapeutics Inc. announces successful advances in RM-1929 clinical development in recurrent Head and Neck Cancer, including Fast Track designation granted by the FDA, initiation of clinical studies in Japan, and plans to start pivotal studies, which will incorporate the evaluation of anti-cancer immune responses, in early 2018.
- Source: Prnewswire
- 747
- January 19, 2018
anti-cancer immune New Approvals RM-1929
Stimwave scoops $50M to step up pain device sales push

Stimwave has raised $50 million to support commercialization of its neuromodulation pain therapies. The financing equips Stimwave to push ahead with its previously disclosed plans to make its devices available across the U.S.
- Source: fiercebiotech
- 606
- January 19, 2018
Market Views neuromodulation pain therapies Series

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.